Literature DB >> 17166599

Examination of real-time PCR for HIV-1 RNA and DNA quantitation in patients infected with HIV-1 BF intersubtype recombinant variants.

N Schvachsa1, G Turk, M Burgard, D Dilernia, M Carobene, M Pippo, M Gómez-Carrillo, C Rouzioux, H Salomon.   

Abstract

The impact of HIV-1 genetic diversity on the performance of laboratory testing is an issue that has to be monitored continuously. An "in-house" real-time PCR assay was developed by the Agence Nationale de Recherche sur le SIDA (ANRS) in France for viral load (VL) quantitation based on the amplification of the HIV-1 long terminal repeat (LTR) region. This technology has not been used in Argentina yet and considering the HIV-1 diversity in the country, a comparative analysis of this assay was undertaken versus the Versant HIV-1 RNA 3.0 Assay (b-DNA). The performance was assessed on 30 drug-naïve HIV-1 infected patients who were characterized previously by phylogenetic analysis of the pol and vpu gene. The results showed that there is a significant linear correlation between values of transformed viral load logarithms measured by both, bDNA and real-time PCR assay and that this assay can be used to quantify viral load in samples from BF-infected patients with the same accuracy and reliability as for B subtype samples. The use of "in-house" real-time PCR to measure DNA in PBMCs correlated strongly with the HIV-1 RNA levels in all specimens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166599     DOI: 10.1016/j.jviromet.2006.11.012

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Assessment of the low-cost Cavidi ExaVir Load assay for monitoring HIV viral load in pediatric and adult patients.

Authors:  Vicki Greengrass; Barbera Lohman; Lisa Morris; Megan Plate; Pauline M Steele; Judd L Walson; Suzanne M Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

2.  Cytotoxic CD8+ T Cells Expressing CXCR5 Are Detectable in HIV-1 Elite Controllers After Prolonged In Vitro Peptide Stimulation.

Authors:  Philipp Adams; Gilles Iserentant; Jean-Yves Servais; Linos Vandekerckhove; Guido Vanham; Carole Seguin-Devaux
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

3.  In-depth validation of total HIV-1 DNA assays for quantification of various HIV-1 subtypes.

Authors:  Sofie Rutsaert; Ward De Spiegelaere; Clarissa Van Hecke; Marie-Angélique De Scheerder; Maja Kiselinova; Karen Vervisch; Wim Trypsteen; Linos Vandekerckhove
Journal:  Sci Rep       Date:  2018-11-22       Impact factor: 4.379

4.  Development of a sensitive, quantitative assay with broad subtype specificity for detection of total HIV-1 nucleic acids in plasma and PBMC.

Authors:  C N Kibirige; M Manak; D King; B Abel; H Hack; D Wooding; Y Liu; N Fernandez; J Dalel; Steve Kaye; N Imami; L Jagodzinski; J Gilmour
Journal:  Sci Rep       Date:  2022-01-28       Impact factor: 4.996

5.  Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.

Authors:  Nicolas Nagot; Chipepo Kankasa; Nicolas Meda; Justus Hofmeyr; Cheryl Nikodem; James K Tumwine; Charles Karamagi; Halvor Sommerfelt; Dorine Neveu; Thorkild Tylleskär; Philippe Van de Perre
Journal:  BMC Infect Dis       Date:  2012-10-06       Impact factor: 3.090

6.  Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study.

Authors:  Sofie Rutsaert; Jean-Marc Steens; Paul Gineste; Basiel Cole; Sam Kint; P Noel Barrett; Jamal Tazi; Didier Scherrer; Hartmut J Ehrlich; Linos Vandekerckhove
Journal:  J Virus Erad       Date:  2019-01-01

7.  Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.

Authors:  Iea Wijting; S L Rutsaert; C Rokx; D M Burger; A Verbon; Jja van Kampen; Cab Boucher; Bja Rijnders; L Vandekerckhove
Journal:  HIV Med       Date:  2018-09-30       Impact factor: 3.180

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.